Canakinumab for Treatment of Adult-Onset Still’s Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial

BACKGROUND: Inhibition of interleukin (IL)-1 represents a promising treatment option in adult-onset Still's disease (AOSD). OBJECTIVE: To investigate the efficacy and safety of canakinumab in patients with AOSD and active joint involvement by means of a multicentre, double-blind, randomised, pl...

Descripción completa

Detalles Bibliográficos
Autores principales: Kedor, Claudia, Listing, Joachim, Zernicke, Jan, Weiß, Anja, Behrens, Frank, Blank, Norbert, Henes, Joerg Christoph, Kekow, Joern, Rubbert-Roth, Andrea, Schulze-Koops, Hendrik, Seipelt, Eva, Specker, Christof, Feist, Eugen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Adult Still’s disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7392486/
https://www.ncbi.nlm.nih.gov/pubmed/32404342
http://dx.doi.org/10.1136/annrheumdis-2020-217155

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7392486/
https://www.ncbi.nlm.nih.gov/pubmed/32404342
http://dx.doi.org/10.1136/annrheumdis-2020-217155

Ejemplares similares